Acute Coronary Syndrome
Conditions
Interventions
the group which administer evolocumab before PCI:evolocumab 140mg was applied 1-3 days before PCI, and then use evolocumab 140mg/2w for 6 months.
the group which administer evolocumab after PCI:evolocumab 140mg was administered 2 weeks after PCI, followed by evolocumab 140mg/2w for 6 months.
Sponsors
Tangdu Hospital of Air Force Millitary Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria can be included: 1. Aged >= 18 and 30 min; (2) ECG indicates AMI (ST segment elevation >= 0.1 mV or ST segment depression >= 0.1 mV); (3) Myocardial injury markers [myoglobin (Myo), troponin I (cTnI) or creatine kinase isoenzyme (CKMB)] are abnormal. Myo reference value 70%; 4. Sign the written informed consent
Exclusion criteria
Exclusion criteria: Anyone who has one or more of the following cannot be selected for this study: (1) Patients with severe autoimmune diseases or malignant tumors; (2) Patients with severe liver, kidney, brain, and lung dysfunction; (3) Patients with hyperthyroidism or hypothyroidism; (4) Patients with a history of chronic heart failure or cardiomyopathy; (5) Patients who are allergic to statins and PCSK9 inhibitors; (6) Received PCSK9 inhibitor treatment in the past three months; (7) The life expectancy of the patient is <= 12 months; (8) The investigator judges that the patient is not suitable for participating in this study for other reasons; (9) The investigator judged that the patient had poor compliance and could not complete the study as required; (10) Patients who are participating in other clinical trials (except for other topics in this project) but have not reached the time limit of the main research endpoint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change in lipid parameters;major cardiovascular adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| secondary cardiovascular adverse events;Inflammatory factors;PCSK9; | — |
Countries
China
Contacts
Public ContactLi Yan
Tangdu Hospital of Air Force Millitary Medical University
Outcome results
None listed